Gene therapy for dominant-negative disorders presents a more difficult challenge than gene therapy for recessive disorders, since even partial replacement of a protein for a recessive disorder can reverse symptoms. Osteogenesis imperfecta (OI) has frequently served as a model disorder for dominant-negative defects of structural proteins. The disease is caused by mutations in type I collagen (COL1A1), the major structural component of bone, skin and other connective tissues. The severity of the phenotype is largely dependent on the ratio of normal to mutant type I procollagen synthesized by cells. Recently, attempts have been made to develop strategies for cell and gene therapies using the adult stem cells from bone marrow referred to as mesenchymal stem cells or marrow stromal cells (MSCs). In this study, we used MSCs from a patient with type III OI who was heterozygous for an IVS 41A+4C mutation in COL1A1. A hybrid genomic/cDNA construct of COL1A1 was transfected into the MSCs and the transfectants were expanded over a 200-fold. Transfected MSCs showed increased expression of the wild-type mRNA and protein. In vitro assays demonstrated that the transfected cells more efficiently differentiated into mineralizing cells. The results indicated that it is possible to overexpress COL1A1 cDNA in OI MSCs and thereby to correct partially the dominant-negative protein defect.
Introduction
A series of special challenges are encountered in developing therapies for genetic diseases that are caused by mutations that generate dominant-negative protein defects. In the example of osteogenesis imperfecta (OI), most patients have heterozygous mutations in either the COL1A1 or COL1A2 gene for type I collagen. 1, 2 Mutations that produce null alleles and reduce the amount of type I collagen by about 50% cause relatively mild phenotypes. In contrast, most severe forms of the disease are caused by mutations that cause synthesis of an abnormal proa1(I) or proa2(I) chain. The abnormal proa chains produce dominant-negative protein defects because the abnormal chains associate with wild-type proa chains into the triple-stranded monomer of type I procollagen. As the presence of a single mutated proa chain alters the characteristic triple-helical conformation of the procollagen monomer, the effect is amplified by two different mechanisms: (a) If the conformation of the procollagen is extensively distorted, the monomers containing one or two mutated proa chains undergo intracellular degradation with a net loss of about three-fourths of the newly synthesized proa chains. (b) With less extensive distortion of conformation, the procollagen is secreted and processed to mutated collagen that copolymerizes with wild-type collagen so that most of the fibrils assembled are abnormal.
One possible strategy for the therapy of dominant mutations is to use stem cells expressing normal alleles to repopulate tissues in which the mutation is expressed. Initial attempts to test this strategy for OI were carried out in transgenic mice that developed brittle bones because they expressed an internally deleted minigene of human COL1A1. 3 The mice were infused with wild-type adult stem cells referred to as mesenchymal stem cells or marrow stromal cells (MSCs) as a source of osteoprogenitors. Infusions of the MSCs produced small but significant increases in both the collagen and mineral content of bone. 3 Subsequently, a two-stage clinical trial was initiated for the use of MSCs in patients with severe OI. [4] [5] [6] In the first stage, the patients underwent marrow ablation followed by a bone marrow transplant from HLAcompatible normal siblings. The rationale for first stage was that whole bone marrow might contain a sufficient number of wild-type MSCs or other osteoprogenitors to improve the status of bone in the patients. Three patients with documented engraftment of donor osteoprogenitors showed increases in body length and total body mineral 3 months after the bone marrow transplants. However, the growth rates slowed or reached plateau levels during a follow-up examination. In the second stage of the trial, the same patients received infusions of MSCs from the same donors without any immunosuppressive therapy, since they now had the immune systems of the donors. Four of the five patients in the second stage of the trial showed an increase in the rate of growth for 6 months after the infusions. The level of engraftment of the donor MSCs was less than 1% in samples of skin and bone. The clinical improvement, therefore, was apparently explained by the MSCs engrafting at sites critical for bone growth that could not be biopsied, differentiating to osteoblasts, and depositing enough wild-type type I collagen to improve mineralization of the bone. In another clinical trial in patients with metachromatic leukodystrophy, systemic infusion of allogeneic wildtype MSCs produced significant improvements in the conduction velocity of peripheral nerves in four of six patients. 7 In still another clinical trial in patients with breast cancer, coinfusions of MSCs with autologous marrow stem cells produced more rapid recovery of the hematopoietic system in 32 patients than in controls. 8 In the experiments reported here, we tried to simplify the strategy for treating patients with OI by transfecting MSCs to overexpress a cDNA for the wild-type COL1A1 gene (Figure 1 ). For the experiments, we used surplus MSCs from a patient with type III OI previously enrolled in a clinical trial. [4] [5] [6] The patient's mutation altered an RNA splice site IVS 41A +4 C in the COL1A1 gene and generated a small amount of abnormal mRNA and proa1 chains lacking the coding sequences of exon 41. 9 The mutation was unusual among mutations producing severe phenotypes because only low levels of abnormal proa chains were detected in cultured fibroblasts and no abnormal proa chains were detected in cultures of osteoblasts from the same patient.
Results
The OI patient
The patient was a 7.5-year-old boy who had severe OI (type III). At birth, he had blue sclerae, osteoporosis, and three fractures of long bones that had developed in utero. Subsequently, he had 35 fractures of long bones and underwent nine orthopedic surgical procedures including placement of intramedullary rods in both humeri, both femurs, both tibiae, and the left ulna. Radiographically, he had severe compressions of vertebral bodies that were present since the age of one, severe osteoporosis with metaphysical flaring of long bones, and popcorn deformities in the growth plates. Bone density by DEXA of L1-L4 indicated a Z score of 6-7 s.d.'s below age-matched normal children. When examined at the age of 6.5 years, his length was the 50th percentile for an 18-month-old boy and he had macrocephaly with a head circumference that was the 50th percentile for a 9-year-old boy.
Generation of a hybrid genomic/cDNA construct for COL1A1
We attempted to develop an experimental strategy whereby MSCs can be isolated from the patient with OI, the cells transfected to overexpress a wild-type collagen gene, and then the cells returned to treat the same patient. As the COL1A1 gene is over 18 kb, we elected to prepare a hybrid genomic/cDNA construct ( Figure 1 ). The construct was prepared by deleting a large central region from a genomic clone containing an internally deleted minigene of the COL1A1 gene and inserting an appropriate coding sequence from a cDNA for the same gene. The central region of the genomic clone was excised through a KpnI site in exon 2 and EcoRI Figure 1 Strategy for design of the genomic/cDNA construct for expression of the COL1A1 gene. The cDNA sequence between exons 2 and 52 was used to replace the central region of a previously described minigene construct (see text). To demonstrate that the construct was incorporated into genomic DNA of the transfected MSCs, PCR assays were used. With genomic DNA from untransfected MSCs, PCR amplified a 597 bp fragment from genomic DNA corresponding to the exon and intron sequences spanning exons 40-42 in the COL1A1 gene ( Figure 2 ). With genomic DNA from transfected MSCs, the same primer set amplified both the 597 bp fragment and a 384 bp fragment that corresponded to the continuous coding sequences of exons 41-43 found in the the hybrid genomic/cDNA construct ( Figure 1 ). Similar results were obtained with the primer pair spanning exons 27-29 in that a 362 bp fragment containing the genomic sequences was obtained from untransfected MSCs and an additional 148 bp fragment corresponding to the cDNA sequences was obtained with transfected MSCs (not shown). A semiquantitative PCR assay for copy number (see Methods) indicated that the copy numbers per cell in two separately transfected cultures were 160769 and 63721 s.d.
Expression of the genomic/cDNA construct as mRNA
To assay expression of the transfected construct as mRNA, two sets of primers were used for RT-PCR assays. One set of primers corresponded to the coding sequences found in exons 40 and 43 and were designed to amplify the small amount of aberrantly spliced mRNA lacking the sequences of exon 41 that was detected in the patient's fibroblasts. 9 With RNA from the patient's untransfected MSCs, the primers generated a major fragment of 384 bp from mRNA transcribed from the normal allele of the patient and the transfected cDNA ( Figure 3 ). There was also a minor fragment of 276 bp corresponding to the low levels of an mRNA lacking the coding sequence of exon 41. The low level of the abnormally spliced mRNA was consistent with the previous report that the abnormally spliced mRNA was only about 15% of the COL1A1 transcripts in fibroblasts from the patient. 9 With RNA from the patient's transfected MSCs, the RT-PCR assays generated the same two bands, but there was an increase in the ratio of the 384 bp to the 276 bp band, indicating that there was overexpression of COL1A1 transcripts for the hybrid genomic/cDNA construct ( Figure 1 ). Correction of a mineralization defect by overexpression of cDNA RR Pochampally et al
To verify that the transfected construct increased the COL1A1 mRNA in the transfected MSCs, RT-PCR assays were carried out with primers for exons 27 and 29. The assays also indicated an increase in wild-type COL1A1 mRNA in the three clones of transfected OI MSCs (bottom panel of Figure 3 ).
Correction of the protein defect in the patient's MSCs
To examine the type procollagen synthesized by the MSCs, the cells were incubated with 3 H-proline and the medium 3 H-proteins examined by PAGE. No distinctive band of abnormal proa1 chains was detected (Figure 4) . The failure to detect the abnormal protein band in the MSCs was consistent with the previous failure to detect abnormal proa1 chains in cultures of the proband's osteoblasts 9 and is probably explained by the previous observation that there are discrepancies in the levels at which mutated proa chains were detected in different cells from the same patients. 15 To assay the synthesis of type I procollagen by the MSCs, the levels of 3 H-proa chains secreted into the medium were compared (Figure 4) . The transfected cells secreted about three-fold more 3 H-protein and about three-fold more 3 H-procollagen.
Correction of the mineralization defect in the patient's MSCs
In further experiments, untransfected and transfected MSCs were assayed for differentiation into osteoblasts. Untransfected MSCs from the patient were relatively inefficient in differentiating into mineralizing cells. In contrast, the same MSCs transfected with the COL1A1 construct readily differentiated into mineralizing cells under the same conditions. The differences were apparent by visual inspection of confluent plates of cells that were incubated in osteogenic medium and then stained with Alizarin Red (Figure 5a ). The differences were also apparent by the size of the nodules formed (Figure 5b ). The differences were confirmed by a quantitative assay for Alizarin Red-stained mineral that demonstrated a 7.3-fold increase compared to nontransfected MSCs from the patient incubated under the same conditions ( Figure 5c ).
Discussion
Much of the current interest in using MSCs for therapies is based on the observations that the cells appear to be part of a natural system for tissue repair. 16 Systemically infused MSCs tend to home to sites of tissue injury and repair the tissues by differentiating so as to replace injured cells in the tissue, by providing factors that enhance the repair of injured cells in the tissue, and perhaps by fusing with injured cells. 16 For many diseases, therefore, it may be adequate to isolate MSCs from a patient to be treated, expand them in culture, and then infuse large numbers of the patient's own MSCs. In genetic diseases, however, either heterologous wild-type cells or genetically corrected cells will be required. Rescue of the genetic defects caused by mutations that Correction of a mineralization defect by overexpression of cDNA RR Pochampally et al have dominant-negative protein defects is particularly challenging.
In the experiments presented here, we attempted to develop a therapeutic strategy for severe OI caused by dominant-negative protein defects in which MSCs are isolated from a patient, the cells are modified to overexpress a wild-type allele for collagen, the cells are expanded in culture, and then returned large numbers of the cells to the same patient so that they can replace a significant number of the patient's own osteoblasts and improve the quality of bone. The strategy was based in part on experiments in transgenic mice demonstrating that relatively small increases in the ratio of expression of wild-type to mutant COL1A1 alleles can change a lethal phenotype into a mild one.
3,17 The same conclusion was supported by studies on mosaic and nonmosaic members of families with OI in which small differences in the expression of the ratio of wild-type to the same mutant allele produced either a mild or a severe phenotype. 18, 19 Therefore, it appears that only a small fraction of the osteoblasts in patients with OI need to be replaced by MSCs overexpressing a wild-type allele to be effective. Since systemically infused MSCs show a remarkable tendency to home to sites of tissue damage and repair the tissues, 16 there is probably no need to directly insert MSCs into critical regions of bone growth.
The results presented here overcome several of the obstacles in developing a therapeutic strategy for OI using MSCs. The hybrid genomic/cDNA construct of the human COL1A1 gene contained all the coding sequences for proa1 chains and most of the elements that experiments in transgenic mice have shown will provide high levels of tissue-specific expression. [10] [11] [12] [13] [14] 17 At the same time, the truncated size of the construct make it more efficient than full-length genomic constructs for transfecting MSCs or other cells. Transfection of MSCs from normal donors with the genomic/cDNA construct gave severely limited expansion of the cells in culture, apparently because of the increased synthesis of collagen and the formation of a more extensive extracellular matrix in the cultures. However, transfected MSCs from the OI patient were readily expanded. The transfected OI MSCs overexpressed the COL1A1 gene from the hybrid genomic/cDNA construct and they synthesized increased amount of type I procollagen. Most importantly, the effects of overexpression of the COL1A1 gene were readily demonstrated by more efficient differentiation of the MSCs into mineralizing osteoblasts. The overexpressed allele apparently provided sufficient amounts of normal collagen fibers to allow mineralization of the matrix to proceed at a rapid rate. In effect, the results suggested that overexpression of the COL1A1 gene in the MSCs may improve the critical defect seen in patients, that is, the inability to synthesize adequate amounts of bone that is fully mineralized.
Efforts are currently being made to correct the gene mutations that cause OI using several different strategies. For example, some investigators are attempting to use hammerhead ribozymes 20 or siRNAs 21 that have been effectively been employed in other contexts. As the present work was being completed, Chamberlain et al 22 published a novel strategy for gene therapy of dominantnegative mutations in OI. Their strategy was to inactivate the mutated alleles in MSCs from OI patients with a gene construct that was designed to insert into a homologous sequence of about 7000 bp of promoter and 5 0 end of the COL1A1 gene. To transfect efficiently MSCs, they placed the construct in an adeno-associated virus vector. With MSCs from two patients with OI, they found that the construct had inserted into either the wild-type or mutated COL1A1 allele in 31 to 90% of the cells that became neomycin resistant. In cultures of all the neomycin-resistant cells, they demonstrated that the protein defect was corrected. Also, they demonstrated rescue of the mineralization defect in a standard assay in which the transfected MSCs were infused into ceramic cubes and the cubes inserted into mice. The strategy of Chamberlain et al has the advantage over the strategy developed here in that it reduces but does not eliminate the chances of insertional mutations in MSCs. It shares with the present strategy the handicap that a neomycin resistance gene was used for the selection of the transfected cells and the presence of the neomycin resistance gene has been found to target cells for destruction in patients, apparently because of immune responses to the protein. 6 The Chamberlain et al strategy has the disadvantage over the strategy developed here in that viral sequences are incorporated into the MSCs, and the presence of viral sequences has frequently caused inactivation of transfected genes in vivo. At the moment, therefore, it is not apparent which the strategies currently being tested will eventually be more appropriate for use in clinical trials.
Methods

Cell culture
Human MSCs were obtained from three healthy donors and from an OI patient previously studied. [4] [5] [6] 9 The protocol for obtaining MSCs from healthy donors was approved by the Institutional Review Board of the Tulane University Health Sciences Center and the protocol for obtaining MSCs from the patient was approved by the Institutional Review Board of the St Jude Children's Research Hospital. The MSCs were obtained from the patient before the patient was transplanted with cells transfected with a neomycin resistance gene. 6 To expand MSCs from the patient, frozen vials of passage 2 cells were plated at high density and incubated overnight to recover viable cells. The medium was DMEM high glucose medium (GIBCO BRL), 20% fetal bovine serum (FBS lot selected for rapid growth of MSCs; Atlanta Biologicals), and 100 U/ml penicillin; and 100 mg/ml streptomycin (GIBCO BRL). The cells were washed with PBS and lifted by incubation with 0.25% trypsin/1 mM EDTA for 5 min at 371C. To obtain passage 3 cells, the cells were then plated at 100 cells/cm 2 and incubated in the same medium until the cells reached about 70% confluency. The medium was replaced every 3 to 4 days and the cells were lifted with trypsin/EDTA. MSCs from normal donors were cultured under the same conditions, except DMEM was replaced with aMEM (GIBCO BRL).
Transfection experiments
Passage 2 MSCs from normal donors were used to test commercially available transfection reagents. Initial trials of transfection experiments were performed in a 24-well Correction of a mineralization defect by overexpression of cDNA RR Pochampally et al tissue culture plate (Nunc) using MSCs from healthy donors. Viable cells were plated at 10 000 cells/cm 2 in a 24-well plate for 24 h. The trial experiments were performed by cotransfecting with the mini-COL1A1 gene 14 and pEGFPluc (Clontech) to assay transient transfectants by luciferase activity, or the mini-COL1A1 gene and pEGFPneo to assay stable transfectants by G418-resistant colonies. The ratio of the mini-COL1A1 DNA to the plasmid DNA was 14:1. The optimal DNA concentration was determined by testing a range of 200 ng-1.5 mg of total DNA added to each well.
The following transfection reagents were tested: Gene Porter2 (Genetherapy Systems), TransFast (Promega), Lipofectamine 2000 (Invitrogen), Lipofectamine Plus (Invitrogen), Fugene 6 (Roche Biochemicals), Xtremegene-6 (Roche Biochemicals) and TransIT (PanVera). Manufacturers recommended protocols were used to transfect the DNA and transient transfection was quantitated by luciferase activity. The cells were incubated in lysis buffer and the activity was determined using luciferase reporter assay system (Clontech). Stable transfectants were obtained by incubating the transient transfectants with 250 mg/ml G418 medium for 15 days.
Based on the results of the trial experiments, the following conditions were used to transfect MSCs from the patient. Passage 3 cells were plated at 10 000 in a 10 cm diameter dish, and at B70% confluency, the cells were cotransfected for overnight using Gene Porter2 with 10 mg the hybrid genomic/cDNA construct together with 0.5 mg pEGFPneo (Stratagene, CA, USA). The transfectants were selected in fresh medium using 250 mg/ml G418 (Invitrogen, CA, USA) for 15 days. The cultures were expanded and maintained under selection media for all further experiments.
Generation of the hybrid genomic/cDNA construct
The construct was prepared using as a backbone a minigene version of the human COL1A1 that contained À2.3 kb of the 5 0 -flanking region and the first five exons linked through introns 5-47 to a 3 0 fragment containing the last six exons and introns together with about 2 kb of the 3 0 -flanking sequences. 14 The central region of the minigene was excised by digestion with KpnI that cleaved a site in exon 2 and EcoRI that cleaved a site in exon 52. The excised central region was then replaced by a KpnI/EcoRI fragment from a complete cDNA for the COL1A1 gene. 14 More specifically, the minigene construct in a plasmid (Bluescript KS+; Stratagene) was cleaved with EcoRI, the digest was extracted with phenol/chloroform, and ethanol precipitated. The sample was digested with KpnI and a 9 kb fragment containing the internally deleted minigene isolated by agarose gel electrophoresis. To replace the internal deletion in the minigene, cDNA from COL1A1 in the pHUC1499 vector was digested with EcoRI and KpnI, and the central fragment of 4 kb purified by agarose gel electrophoresis. The internally deleted minigene and the internal fragment for the cDNA were then ligated in a 1:4 ratio with T4 ligase (New England Biolabs). The ligation mixture was used to transform competent bacteria (DH5a; Gibco), the plasmid isolated, and its structure confirmed by restriction mapping and partial DNA sequencing.
PCR assays for incorporation of the construct into genomic DNA
The transfectants and control cultures were harvested with trypsin/EDTA and genomic DNA was extracted (DNeasy tissue extraction kit; Qiagen, CA, USA). About 100 ng of DNA was used to amplify COL1A1 gene between exons 27 and 29 and exons 40 and 42 using the following primers: 5 0 -GGT CCT GCT GGC AAA GAT GGA-3 0 and 5 0 -TTG CCT GCT TCA CCT GGA GGA CCA-3 0 and 5 0 -CAA AGA AGG CGG CAA AGG TCC CCG TGG TGAG-3 0 and 5 0 -CTC ACG TCC AGA TTC ACC AGG GGG TCC AGC-3 0 , respectively. PCR conditions were denaturation at 941C for 90 s, annealing at 551C for 1 min, and extension at 721C for 1 min for 29 cycles.
To assay copy number, a semiquantitative PCR assay was used using the primers for exons 40 and 42 and the same conditions as were used to amplify the genomic DNA. A standard curve was prepared with mixtures of DNA from untransfected MSCs and 0.1-100 pg of plasmid containing the hybrid genomic/cDNA construct adjusted to 100 ng of total DNA. The products were separated on an agarose gel, stained with ethidium bromide, and scanned (Scion Image Software). Assays in triplicate of DNA from two cultures of transfected OI MSCs indicated that the content of plasmid containing the construct ranged from 0.1 to 1 pg/100 ng of DNA. Copy numbers per cell were calculated assuming a molecular weight for the plasmid containing the hybrid COL1A1 construct of 15.5 kb.
RT-PCR assays for expression of the construct
The transfectants and control cultures were treated with 100 mg/ml cycloheximide (Sigma) for 2 h to block translation. RNA was isolated from 0.5 Â 10 6 (RNAesy RNA isolation kit; Qiagen Inc.). About 50 ng of RNA was used to perform one-step RT-PCR (Titan One step RT-PCR kit; Roche Biochemicals). The following primer sets spanning exons 40 and 43 were used: 5 0 -CAA AGA AGG CGG CAA AGG TCC CCG TGG TGAG-3 0 and 5 0 -GGA GAA CCG TCT CGT CCA GGG GAA CCT TCG-3 0 . 9 The conditions were the same as for the PCR assay of genomic DNA. The products were separated on an agarose gel and stained with ethidium bromide.
Assay of procollagen synthesis
To assay procollagen synthesis, OI MSCs were plated at 2000 cells/cm 2 in 10 cm plates. After 2 days, the cells are incubated for 2 h in 3 ml of serum-free medium containing 50 mg/ml ascorbic acid, followed by incubation with 50 mCi/ml of 3.96 tBq/mmol L- [2, 3, 4, H]proline (Amersham, UK) in serum-free medium for 16 h. The radiolabeled medium was dialyzed twice overnight against 100 mM ammonium carbonate buffer using dialysis cassettes (Slidealyzer; Pierce, CA, USA). The dialyzed medium was assayed by scintillation counting for 3 Hprotein. The remainder of the medium was lyophilized, suspended in 200 ml of protein loading buffer, and separated by 10% SDS-urea-PAGE.
The gel was dried and autoradiography performed. The intensity of bands was analyzed using Scion Image Analysis Software. The percent of peaks of proa chains divided by the total density of the lane.
Assays for mineralization
Mineralization assay was performed by plating the cells at 1000 cells/cm 2 in 10 cm plates and incubation for 7 days in DMEM/20% FBS medium. The medium was replaced with mineralization medium that with contained 20 mM b-glycerol phosphate, 50 ng/ml thyroxin, 10 mM DEX, and 50 mg/ml ascorbate-2-phosphate in DMEM with 20% FBS. After 3 weeks, the mineralized colonies were fixed in 10% formalin for 1 h and stained with 0.5% fresh Alizarin Red (pH 4.1; 0.1 g Alizarin Red, Sigma; 5 ml water; and 1 ml ammonium hydroxide) for 5 min. The stained plates were washed with distilled water to remove nonspecific staining. For a quantitative assay, 23 the stained cells were then incubated for 15 min with 10% (w/v) cetylpyridinium chloride in 10 mM sodium phosphate, pH 7.0. The extracted stain was transferred to a 96-well plate, and the absorbance at 562 nm was measured using a microplate reader/ spectrophotometer (BioRad Inc.). The concentration of Alizarin Red staining in the samples was determined by comparing the absorbance values with those obtained from an Alizarin Red standard curve.
